<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
      <restricted-by>pmc</restricted-by>
    </processing-meta>
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">NPJ Precis Oncol</journal-id>
        <journal-id journal-id-type="iso-abbrev">NPJ Precis Oncol</journal-id>
        <journal-id journal-id-type="pmc-domain-id">3403</journal-id>
        <journal-id journal-id-type="pmc-domain">npjprecisoncol</journal-id>
        <journal-title-group>
          <journal-title>NPJ Precision Oncology</journal-title>
        </journal-title-group>
        <issn pub-type="epub">2397-768X</issn>
        <publisher>
          <publisher-name>Nature Publishing Group</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC9807588</article-id>
        <article-id pub-id-type="pmcid-ver">PMC9807588.1</article-id>
        <article-id pub-id-type="pmcaid">9807588</article-id>
        <article-id pub-id-type="pmcaiid">9807588</article-id>
        <article-id pub-id-type="pmid">36593350</article-id>
        <article-id pub-id-type="doi">10.1038/s41698-022-00342-z</article-id>
        <article-id pub-id-type="publisher-id">342</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Brief Communication</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author" equal-contrib="yes">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4154-0567</contrib-id>
            <name name-style="western">
              <surname>Mandelker</surname>
              <given-names initials="D">Diana</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author" equal-contrib="yes">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7310-7824</contrib-id>
            <name name-style="western">
              <surname>Marra</surname>
              <given-names initials="A">Antonio</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Mehta</surname>
              <given-names initials="N">Nikita</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Selenica</surname>
              <given-names initials="P">Pier</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Yelskaya</surname>
              <given-names initials="Z">Zarina</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Yang</surname>
              <given-names initials="C">Ciyu</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Somar</surname>
              <given-names initials="J">Joshua</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Mehine</surname>
              <given-names initials="M">Miika</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Misyura</surname>
              <given-names initials="M">Maksym</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Basturk</surname>
              <given-names initials="O">Olca</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Latham</surname>
              <given-names initials="A">Alicia</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Carlo</surname>
              <given-names initials="M">Maria</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Walsh</surname>
              <given-names initials="M">Michael</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Stadler</surname>
              <given-names initials="ZK">Zsofia K.</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Offit</surname>
              <given-names initials="K">Kenneth</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bandlamudi</surname>
              <given-names initials="C">Chaitanya</given-names>
            </name>
            <xref ref-type="aff" rid="Aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hameed</surname>
              <given-names initials="M">Meera</given-names>
            </name>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chi</surname>
              <given-names initials="P">Ping</given-names>
            </name>
            <xref ref-type="aff" rid="Aff3">3</xref>
          </contrib>
          <contrib contrib-type="author" corresp="yes">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2969-3173</contrib-id>
            <name name-style="western">
              <surname>Reis-Filho</surname>
              <given-names initials="JS">Jorge S.</given-names>
            </name>
            <address>
              <email>reisfilj@mskcc.org</email>
            </address>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <contrib contrib-type="author" corresp="yes">
            <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9214-1454</contrib-id>
            <name name-style="western">
              <surname>Ceyhan-Birsoy</surname>
              <given-names initials="O">Ozge</given-names>
            </name>
            <address>
              <email>birsoyo@mskcc.org</email>
            </address>
            <xref ref-type="aff" rid="Aff1">1</xref>
          </contrib>
          <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Department of Pathology and Laboratory Medicine, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, NY USA </aff>
          <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Marie-Josee and Henry R. Kravis Center for Molecular Oncology, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, NY USA </aff>
          <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Department of Medicine, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, NY USA </aff>
        </contrib-group>
        <pub-date pub-type="epub">
          <day>2</day>
          <month>1</month>
          <year>2023</year>
        </pub-date>
        <pub-date pub-type="collection">
          <year>2023</year>
        </pub-date>
        <volume>7</volume>
        <issue-id pub-id-type="pmc-issue-id">425019</issue-id>
        <elocation-id>1</elocation-id>
        <history>
          <date date-type="received">
            <day>21</day>
            <month>9</month>
            <year>2022</year>
          </date>
          <date date-type="accepted">
            <day>14</day>
            <month>12</month>
            <year>2022</year>
          </date>
        </history>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>02</day>
              <month>01</month>
              <year>2023</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>04</day>
              <month>01</month>
              <year>2023</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2023-01-04 00:10:11.833">
              <day>04</day>
              <month>01</month>
              <year>2023</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>© The Author(s) 2022</copyright-statement>
          <license>
            <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
            <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
          </license>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41698_2022_Article_342.pdf"/>
        <abstract id="Abs1">
          <p id="Par1">Traditional genetic testing for patients with gastrointestinal stromal tumors (GISTs) focus on those with syndromic features. To assess whether expanded genetic testing of GIST patients could identify hereditary cancer predisposition, we analyzed matched tumor-germline sequencing results from 103 patients with GISTs over a 6-year period. Germline pathogenic/likely pathogenic (P/LP) variants in GIST-associated genes (<italic toggle="yes">SDHA, SDHB, SDHC, NF1, KIT</italic>) were identified in 69% of patients with <italic toggle="yes">KIT/PDGFRA</italic>-wildtype GISTs, 63% of whom did not have any personal or family history of syndromic features. To evaluate the frequency of somatic versus germline variants identified in tumor-only sequencing of GISTs, we analyzed 499 de-identified tumor-normal pairs. P/LP variants in certain genes (e.g., <italic toggle="yes">BRCA1/2, SDHB</italic>) identified in tumor-only sequencing of GISTs were almost exclusively germline in origin. Our results provide guidance for genetic testing of GIST patients and indicate that germline testing should be offered to all patients with <italic toggle="yes">KIT/PDGFRA</italic>-wildtype GISTs regardless of their history of syndromic features.</p>
        </abstract>
        <kwd-group kwd-group-type="npg-subject">
          <title>Subject terms</title>
          <kwd>Molecular medicine</kwd>
          <kwd>Cancer genetics</kwd>
          <kwd>Cancer genomics</kwd>
        </kwd-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000054</institution-id>
                <institution>U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)</institution>
              </institution-wrap>
            </funding-source>
            <award-id>P30 CA008748</award-id>
            <award-id>P50 CA247749 01</award-id>
            <principal-award-recipient>
              <name name-style="western">
                <surname>Reis-Filho</surname>
                <given-names>Jorge S.</given-names>
              </name>
              <name name-style="western">
                <surname>Ceyhan-Birsoy</surname>
                <given-names>Ozge</given-names>
              </name>
            </principal-award-recipient>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution>Marie-Josée and Henry R. Kravis Center for Molecular Oncology, the Precision, Interception and Prevention Program; the Robert and Kate Niehaus Center for Inherited Cancer Genomics</institution>
            </funding-source>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution>U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)</institution>
            </funding-source>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100001006</institution-id>
                <institution>Breast Cancer Research Foundation (BCRF)</institution>
              </institution-wrap>
            </funding-source>
          </award-group>
        </funding-group>
        <funding-group>
          <award-group>
            <funding-source>
              <institution-wrap>
                <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100009634</institution-id>
                <institution>Susan G. Komen (Susan G. Komen Breast Cancer Foundation)</institution>
              </institution-wrap>
            </funding-source>
          </award-group>
        </funding-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>issue-copyright-statement</meta-name>
            <meta-value>© The Author(s) 2023</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <p id="Par2">Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal system<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Up to 85–90% of GISTs harbor activating mutations in <italic toggle="yes">KIT</italic> or <italic toggle="yes">PDGFRA</italic> and respond to imatinib or sunitinib therapies<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup>. The remaining 10–15% are <italic toggle="yes">KIT/PDGFRA</italic>-wildtype and may have somatic loss-of-function (LOF) mutations in succinate dehydrogenase (SDH)-complex subunits (<italic toggle="yes">SDHA/B/C/D</italic>) or <italic toggle="yes">NF1</italic>, activating mutations in <italic toggle="yes">BRAF</italic>, <italic toggle="yes">FGFR1</italic>, or <italic toggle="yes">NTRK</italic> translocations, or may be driven by germline alterations<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR5">5</xref></sup>. Germline pathogenic variants in SDH-complex genes<sup><xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR8">8</xref></sup>, <italic toggle="yes">NF1</italic><sup><xref ref-type="bibr" rid="CR9">9</xref></sup>, <italic toggle="yes">KIT</italic><sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>, and <italic toggle="yes">PDGFRA</italic><sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup> have been associated with the development of GISTs. Currently, no standard guidelines exist for germline testing in GIST patients. Previous studies on germline contribution to GISTs focused on patients with <italic toggle="yes">KIT/PDGFRA</italic>-wildtype tumors, particularly those with syndromic features, and targeted selected genes<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>, given the assumption that GISTs resulting from germline alterations are frequently syndromic<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup>. Recent studies, however, demonstrated that syndromic features may be absent in a large proportion of patients with hereditary cancer predisposition<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>.</p>
      <p id="Par3">Owing to the restrictive pre-selection of patients and genes for genetic testing, the contribution of germline variants to GIST development remains to be fully characterized. To assess whether expanded genetic testing of unselected GIST patients could identify individuals with hereditary predisposition, we analyzed matched tumor-germline sequencing results from 103 patients with GISTs treated at Memorial Sloan Kettering (MSK) Cancer Center (MSKCC) over a 6-year period (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>). Testing was performed using MSK Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> and included 76–90 cancer predisposition genes (Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>).</p>
      <p id="Par4">Overall, of the 103 patients with GISTs in this cohort, 24 (23%) had a germline pathogenic/likely pathogenic (P/LP) variant in a GIST-associated gene. The cohort of 103 patients included 58 with somatic mutations in <italic toggle="yes">KIT</italic>, 10 with somatic mutations in <italic toggle="yes">PDGFRA</italic>, and 35 with <italic toggle="yes">KIT/PDGFRA</italic>-wildtype GISTs (Fig. <xref rid="Fig1" ref-type="fig">1</xref>, Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>). Strikingly, 69% (24/35) of individuals with a <italic toggle="yes">KIT/PDGFRA</italic>-wildtype GIST harbored a germline P/LP variant in a GIST-associated gene (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>, Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>). These included 16 patients with SDH-complex gene (seven <italic toggle="yes">SDHA</italic>, seven <italic toggle="yes">SDHB</italic>, two <italic toggle="yes">SDHC</italic>), seven with <italic toggle="yes">NF1</italic>, and one with <italic toggle="yes">KIT</italic> germline P/LP variants, accounting for 46%, 20%, and 3% of patients with <italic toggle="yes">KIT/PDGFRA</italic>-wildtype GISTs, respectively. Seven (20%) of the patients with <italic toggle="yes">KIT/PDGFRA</italic>-wildtype GISTs had other somatic driver mutations: four with <italic toggle="yes">NF1</italic> biallelic, one with <italic toggle="yes">SDHA</italic> biallelic LOF, and two with <italic toggle="yes">BRAF</italic> activating mutations. Three tumors from patients without germline P/LP variants had monoallelic <italic toggle="yes">SDHB</italic> or <italic toggle="yes">SDHD</italic> mutations, and due to the limitations in detecting LOH or a second mutation, were considered as inconclusive for somatic mutation status. One patient had neither germline nor somatic mutations identified in GIST-associated genes. <italic toggle="yes">SDHC</italic> promoter methylation<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> was tested and ruled out in tumors without conclusive driver mutations. Overall, germline P/LP variants in GIST-associated genes were identified in 96% (24/25) of patients with somatic driver-negative tumors.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Mutational landscape of GISTs from 103 patients who received germline genetic testing.</title><p>Tumor characteristics (site, metastasis status, focality, type) and the effects of somatic mutations are color coded according to the legend. LOH is displayed by a diagonal bar and second somatic mutation (second somatic hit) is displayed by a dot. The numbers on the right side of each row refer to the percentage of tumors with that given gene mutation in the overall cohort of 103 patients.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e611" position="float" orientation="portrait" xlink:href="41698_2022_342_Fig1_HTML.jpg"/></fig><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Detection of germline P/LP variants in GIST patients based on somatic profiles.</title><p><bold>a</bold> Proportion of patients with P/LP variants in GIST-associated genes in the cohort of 103 patients who received germline genetic testing. Percentages are plotted and displayed on the bar graphs. Error bars represent confidence intervals calculated by the Clopper-Pearson method. <bold>b</bold> Distribution of germline (blue) and somatic (orange) P/LP variants detected in tumor-only sequencing analysis of de-identified GISTs from 499 patients. Data from all tumors (left), <italic toggle="yes">KIT</italic>-mutant tumors (middle), and <italic toggle="yes">KIT</italic>-wildtype tumors (right) are presented. Numbers displayed on the right of each gene data on each plot represent the number of tumor samples with variants identified in each gene in that group of tumors.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e634" position="float" orientation="portrait" xlink:href="41698_2022_342_Fig2_HTML.jpg"/></fig></p>
      <p id="Par5">Germline P/LP variants in cancer predisposition genes not known to be associated with GISTs were identified in eight patients, all of whom had <italic toggle="yes">KIT/PDGFRA</italic>-mutant GISTs. These included alterations affecting <italic toggle="yes">TP53, MLH1, BRCA2</italic>, and <italic toggle="yes">RECQL</italic> in one patient each, as well as two patients with <italic toggle="yes">APC</italic> p.Ile1307Lys low-penetrance variant and two with monoallelic <italic toggle="yes">MUTYH</italic> variants (Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>). Loss-of-heterozygosity (LOH) or a second somatic mutation in these genes were not observed in the tumors. The patient with <italic toggle="yes">MLH1</italic> alteration had a microsatellite-stable tumor and homologous recombination deficiency signature was not detected in the patient with <italic toggle="yes">BRCA2</italic> alteration, suggesting that these variants likely constitute incidental findings.</p>
      <p id="Par6">Patients with germline GIST-associated variants had a younger median age-of-onset (39.5 vs 52 years, <italic toggle="yes">p</italic> = 0.01), and were more likely to have metastatic disease (50% vs 20%; <italic toggle="yes">p</italic> = 0.01) and multifocal lesions (50% vs 18%, <italic toggle="yes">p</italic> = 0.01) at the time of testing compared to those lacking P/LP variants in these genes (Supplementary Table <xref rid="MOESM1" ref-type="media">3</xref>).</p>
      <p id="Par7">Most patients with germline P/LP variants in GIST-associated genes did not present with syndromic features. Of the 16 patients with germline SDH-complex gene defects, only one had syndromic presentation (history of paraganglioma), and another had family history (father with paraganglioma), whereas 88% (14/16) had no personal or family history of syndromic features at the time of testing. Thirteen patients had SDHB immunohistochemistry performed, and tumors demonstrated absence of SDHB expression. While 86% (6/7) of patients with germline <italic toggle="yes">NF1</italic> alterations had a history of NF1 features, for one patient, identification of the germline <italic toggle="yes">NF1</italic> variant led to the recognition of café-au-lait spots and mild axillary/inguinal freckling, consistent with mild neurofibromatosis<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Additionally, one (1%) of 103 patients had a pathogenic germline <italic toggle="yes">KIT</italic> variant (p.Lys509Ile)<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>. Overall, 63% (15/24) of patients with germline GIST-associated variants did not have personal or family history of syndromic features, suggesting that a significant proportion of <italic toggle="yes">KIT/PDGFRA</italic>-wildtype GISTs appearing to be sporadic may have underlying germline alterations.</p>
      <p id="Par8">Tumor-only sequencing is commonly performed to assess somatic alterations and may reveal germline variants. To determine the frequency of somatic versus germline variants identified in tumor-only sequencing of GISTs, we analyzed a cohort of de-identified 499 GISTs that received paired tumor-normal sequencing using MSK-IMPACT, including tumors from the 103 patients in the initial analysis and 396 patients who did not consent to germline testing (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>). To mimic a tumor-only sequencing analysis approach, the sequencing data from these tumors was used in an unmatched manner, without subtracting the variant calls detected in the paired normal sequencing data. For distinguishing germline versus somatic variants in the tumor sequencing data, variant allele fraction (VAF) thresholds for predicting germline variants in tumor sequencing recommended by the European Society of Medical Oncology (VAF of &gt;30% for single nucleotide variants (SNVs) and &gt;20% for insertions and deletions (indels))<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> were applied to P/LP variants identified in the tumors. The matched normal blood sequencing data was used to confirm the germline versus somatic origin of the variants detected in tumors. These VAF thresholds correctly distinguished all true germline and somatic P/LP variants identified in the tumors, as determined by comparison with the matched normal blood sequencing data. Of the 69 <italic toggle="yes">KIT/PDGFRA</italic>-wildtype GISTs in this cohort, 33 (48%) were found to harbor germline P/LP variants in GIST-associated genes, consistent with our findings in the cohort who received germline testing. P/LP variants identified in tumor-only sequencing of GISTs were almost exclusively germline in certain genes, such as <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic> (4/4 variants), and <italic toggle="yes">SDHB</italic> (10/11 variants). Conversely, P/LP variants in genes such as <italic toggle="yes">KIT</italic> (430/431 variants) and <italic toggle="yes">RB1</italic> (9/9 variants) were primarily somatic (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). These observations can help identify the subset of GIST patients to offer germline testing based on tumor-only sequencing results.</p>
      <p id="Par9">This study has limitations. Detailed clinical assessments could only be performed for 103 patients who consented to germline testing. Additionally, limitations exist in detecting certain variants such as structural variants or low-level mosaicism.</p>
      <p id="Par10">Despite these limitations, our results support that germline testing should be offered to all patients with <italic toggle="yes">KIT/PDGFRA</italic>-wildtype GISTs, regardless of their history of syndromic features, and should target all GIST-associated genes at minimum. In our cohort of 103 patients with GISTs who consented to germline analysis, 23% had a germline P/LP variant in a GIST-associated gene, and an additional 8% had a germline P/LP variant in an additional cancer susceptibility gene, suggesting that all GIST patients, regardless of their tumor testing status, could benefit from germline testing. Germline alterations in GIST-associated genes may also confer high risk for other cancers, such as paragangliomas and pheochromocytomas for SDH-complex genes and nerve sheath tumors, breast cancer, and gliomas for <italic toggle="yes">NF1</italic>. Therefore, their identification has critical implications for future cancer surveillance and clinical management of the patients, as well as appropriate care of their at-risk family members. Determining the somatic and germline alterations underlining tumor development is also critical for appropriate targeted therapy selections, as SDH-deficient and <italic toggle="yes">NF1</italic>-related tumors are known to respond poorly to traditional imatinib therapy and differentiating the different genetic alterations in <italic toggle="yes">KIT/PDGFRA</italic>-wildtype GISTs can guide treatment choices<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup>. Finally, our analysis on 499 tumor-normal pairs suggests that the identification of P/LP variants in certain genes in tumor-only sequencing of GISTs may indicate germline testing. Additional large-scale studies on the phenotypic spectrum of GIST-associated genes will help in developing clinical guidelines for expanded genetic testing in GIST patients.</p>
      <sec id="Sec1">
        <title>Methods</title>
        <sec id="Sec2">
          <title>Patient cohort</title>
          <p id="Par11">The de-identified cohort consisted of tumor-normal pairs from 499 consecutive patients with GIST who were treated at MSKCC and had MSK-IMPACT (ClinicalTrials.gov identifier, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01775072">NCT01775072</ext-link>) paired tumor-blood DNA sequencing test<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup> between April 2015 and June 2021. Germline analysis cohort consisted of 103 patients with GIST, who were a subset of the larger cohort and prospectively consented to germline analysis as part of MSK-IMPACT. Patients were ascertained through their treating physicians and referral was at the discretion of the physicians. The presence/absence of personal/family history of syndromic features were determined based on review of pre-testing and post-testing clinical geneticist and oncologist physical examination and family history assessments that included inquiry about features related to genetic disorders associated with the development of GISTs. All patients provided written informed consent for testing under a Memorial Sloan Kettering Cancer Center Institutional Review Board (IRB)-approved protocol (IRB#12-245).</p>
        </sec>
        <sec id="Sec3">
          <title>MSK-IMPACT testing</title>
          <p id="Par12">MSK-IMPACT is a New York State Department of Health approved assay and was performed in our CLIA-approved laboratory. Next-generation sequencing was performed on DNA isolated from matched blood and tumor specimens, as described<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR21">21</xref>–<xref ref-type="bibr" rid="CR23">23</xref></sup>. DNA fragments were captured using custom-designed biotinylated probes (NimbleGen) and sequenced on an Illumina HiSeq 2500 as paired-end 100 bp reads<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>. Tumor testing included 341, 410, or 505 genes, depending on the panel used for testing. Germline testing included 76, 88, or 90 hereditary cancer predisposition genes for 18, 71, and 14 patients, respectively (Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>)<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>. Variants were called using MuTect<sup><xref ref-type="bibr" rid="CR24">24</xref></sup> and Genome Analysis Toolkit (GATK) Haplotype caller<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. Copy number variants (deletions and duplications of single or multiple exons) were detected and analyzed using an in-house developed pipeline<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>, which identifies copy number aberrations by comparing sequence coverage of targeted regions to standard diploid normal. Variants were filtered using 25% (for SNVs) and 15% (for indels) variant allele fraction and 20× coverage thresholds. All variants with &lt;1% population frequency in the Genome Aggregation Database (gnomAD)<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> were reviewed and classified by clinical molecular geneticists and molecular genetic pathologists based on the American College of Medical Genetics and Genomics (ACMG) guidelines<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>.</p>
        </sec>
        <sec id="Sec4">
          <title>LOH, microsatellite instability (MSI), and mutation signature analyses</title>
          <p id="Par13">LOH was determined using segmented allele-specific copy number calls from FACETS tool<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>, an open-source software that utilizes aligned sequence bam files from next-generation sequencing and performs analysis for joint segmentation of total- and allele-specific read counts and integer copy number calls corrected for tumor purity, ploidy and clonal heterogeneity to estimate LOH. Segments with a minor allele copy number of 0 were classified as having LOH. The allele undergoing LOH was determined based on the VAF of the germline variants in the tumor. MSI status of the tumors were assessed using clinically validated MSIsensor program<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>, which computes length distributions of microsatellites per designated regions in paired tumor and normal sequence data and identifies the percentage of microsatellite loci that are unstable in the tumor genome as compared to its matched normal. Evidence of MSI at ≥10% of analyzed loci was considered as MSI-high, ≥3 to &lt;10% was considered as indeterminate MSI status, and &lt;3% were considered as microsatellite stable. Tumor mutation signatures were determined based on MSK-IMPACT data by assigning the mutations in each sample to constituent mutation signatures from a set of 30 signatures described previously<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>.</p>
        </sec>
        <sec id="Sec5">
          <title><italic toggle="yes">SDHC</italic> promoter methylation testing</title>
          <p id="Par14">DNA isolated from tumor tissues were subjected to bisulfite treatment, followed by PCR and PyroSequencing, and <italic toggle="yes">SDHC</italic> promoter methylation status was evaluated as described<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Samples were run with in-house unmethylated DNA as negative control and CpGenome Human Methylated DNA standard (EMD Millipore Corp., MA, USA) as positive control. Genomic DNA was treated with bisulfite conversion using EpiTect Bisulfite Kit (Qiagen, Hilden, Germany). Each PCR amplification reaction of bisulfite-treated DNA was performed in 50 µl reaction consisting of 35 µl SIGMA JumpStart REDTaq ReadyMix PCR reaction Mix (Sigma–Aldrich Inc., MO, USA), 1 µl 10 µM forward primer (5’-GAAAATAATTAGTAAATTAGTTAGGTAG-3’), 1 µl 10 µM biotinylated reverse primer (5’- ACTAAAATCACCTCAACAACAAC-3’), 11 µl of PCR grade water, and 100 ng bisulfite-treated DNA. PCR cycling conditions were initial step 96 °C for 5 min, followed by 36 cycles with denaturation at 94 °C for 30 sec, annealing at 55 °C for 45 sec, and elongation at 72 °C for 60 sec, with a final extension at 72 °C for 5 min. Bisulfite pyrosequencing was performed on a PyroMark Q24 pyrosequencer system (Qiagen) with Streptavidin Sepharose Beads (GE Healthcare Bioscience, Uppsala, Sweden), PyroMark Gold Q24 reagents kit (Qiagen), PyroMark workstation buffers (Qiagen), and sequencing primer (5’- GTTATATGATATTTTTAATTT-3’). Data analysis was performed using PyroMark Q24 Software 2.0 (Qiagen) with CpG analysis mode.</p>
        </sec>
        <sec id="Sec6">
          <title>Immunohistochemistry</title>
          <p id="Par15">Immunohistochemistry for SDHA and SDHB proteins was performed as part of clinical assessment of tumors on formalin-fixed, paraffin-embedded tissue sections using AB14715 (Abcam, Cambridge MA, USA) and HPA002868 (Sigma–Aldrich, St. Louis, MO, USA) antibodies, respectively. Briefly, 4 μm thick sections from representative tissue blocks were processed using the Ventana Discovery XT system with antigen retrieval (CC1 solution, 60 min), primary antibody (1:6400 dilution for SDHA (AB14715) and 1:800 dilution for SDHB (HPA002868) antibodies), and OptiView DAB immunohistochemistry detection steps (Ventana Medical Systems, Tucson, AZ, USA).</p>
        </sec>
        <sec id="Sec7">
          <title>Reporting summary</title>
          <p id="Par16">Further information on research design is available in the <xref rid="MOESM2" ref-type="media">Nature Research Reporting Summary</xref> linked to this article.</p>
        </sec>
      </sec>
      <sec sec-type="supplementary-material">
        <title>Supplementary information</title>
        <sec id="Sec8">
          <p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41698_2022_342_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Data Files</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41698_2022_342_MOESM2_ESM.pdf" position="float" orientation="portrait"><caption><p>REPORTING SUMMARY</p></caption></media></supplementary-material>
</p>
        </sec>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn>
          <p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
        </fn>
        <fn>
          <p>These authors contributed equally: Diana Mandelker, Antonio Marra.</p>
        </fn>
      </fn-group>
      <sec>
        <title>Supplementary information</title>
        <p>The online version contains supplementary material available at 10.1038/s41698-022-00342-z.</p>
      </sec>
      <ack>
        <title>Acknowledgements</title>
        <p>This work was partly supported by the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, the Precision, Interception and Prevention Program; the Robert and Kate Niehaus Center for Inherited Cancer Genomics; and the National Institutes of Health (NIH)/National Cancer Institute (NCI) Cancer Center Support Grant (P30 CA008748). J.S.R.-F. is funded in part by the NIH/NCI P50 CA247749 01, a Breast Cancer Research Foundation grant and a Susan G Komen leadership grant.</p>
      </ack>
      <notes notes-type="author-contribution">
        <title>Author contributions</title>
        <p>Study conception and design: D.M., A.M., J.S.R.-F., and O.C.-B.; Acquisition of data: All authors; Data analysis and interpretation: D.M., A.M., N.M., P.S., Z.Y., C.Y., M.M., C.B., J.S.R.-F., and O.C.-B.; Writing of manuscript: D.M., A.M., J.S.R.-F., and O.C.-B.; Review and final approval of manuscript: All authors.</p>
      </notes>
      <notes notes-type="data-availability">
        <title>Data availability</title>
        <p>Identifying information for the patients is not available to protect patient privacy. All de-identified tumor DNA sequencing results and associated clinical data for the patients in this study are publicly available in the open-source cBioPortal for Cancer Genomics at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cbioportal.org/study/summary?id=gist_msk_2022">https://www.cbioportal.org/study/summary?id=gist_msk_2022</ext-link>.</p>
      </notes>
      <notes notes-type="data-availability">
        <title>Code availability</title>
        <p>The MSK-IMPACT data analysis pipeline is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/rhshah/IMPACT-Pipeline">https://github.com/rhshah/IMPACT-Pipeline</ext-link>. The mutational signature decomposition code is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://github.com/mskcc/mutation-signatures">https://github.com/mskcc/mutation-signatures</ext-link>.</p>
      </notes>
      <notes id="FPar1" notes-type="COI-statement">
        <title>Competing interests</title>
        <p id="Par17">J.S.R.-F. reports receiving personal/consultancy fees from Goldman Sachs, REPARE Therapeutics, Paige.AI, Personalis and Eli Lilly, membership of the scientific advisory boards of VolitionRx, REPARE Therapeutics, Paige.AI and Personalis, membership of the Board of Directors of Grupo Oncoclinicas, and ad hoc membership of the scientific advisory boards of Roche Tissue Diagnostics, Ventana Medical Systems, Novartis, Genentech, MSD, Daiichi Sankyo and InVicro, outside the scope of this study. The remaining authors declare no competing interests.</p>
      </notes>
      <ref-list id="Bib1">
        <title>References</title>
        <ref id="CR1">
          <label>1.</label>
          <mixed-citation publication-type="other">Brcic, I., Argyropoulos, A. &amp; Liegl-Atzwanger, B. Update on molecular genetics of gastrointestinal stromal tumors. <italic toggle="yes">Diagnostics (Basel)</italic>10.3390/diagnostics11020194 (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics11020194</pub-id><pub-id pub-id-type="pmcid">PMC7912114</pub-id><pub-id pub-id-type="pmid">33525726</pub-id></mixed-citation>
        </ref>
        <ref id="CR2">
          <label>2.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Bachet</surname>
                <given-names>JB</given-names>
              </name>
              <name name-style="western">
                <surname>Emile</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors</article-title>
            <source>Appl. Clin. Genet.</source>
            <year>2010</year>
            <volume>3</volume>
            <fpage>85</fpage>
            <lpage>101</lpage>
            <pub-id pub-id-type="pmid">23776354</pub-id>
            <pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/TACG.S7191</pub-id>
            <pub-id pub-id-type="pmcid">PMC3681166</pub-id>
          </element-citation>
        </ref>
        <ref id="CR3">
          <label>3.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Mei</surname>
                <given-names>L</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Gastrointestinal stromal tumors: The GIST of Precision Medicine</article-title>
            <source>Trends Cancer</source>
            <year>2018</year>
            <volume>4</volume>
            <fpage>74</fpage>
            <lpage>91</lpage>
            <pub-id pub-id-type="doi">10.1016/j.trecan.2017.11.006</pub-id>
            <pub-id pub-id-type="pmid">29413424</pub-id>
          </element-citation>
        </ref>
        <ref id="CR4">
          <label>4.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Gopie</surname>
                <given-names>P</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Classification of gastrointestinal stromal tumor syndromes</article-title>
            <source>Endocr. Relat. Cancer</source>
            <year>2018</year>
            <volume>25</volume>
            <fpage>R49</fpage>
            <lpage>R58</lpage>
            <pub-id pub-id-type="doi">10.1530/ERC-17-0329</pub-id>
            <pub-id pub-id-type="pmid">29170162</pub-id>
          </element-citation>
        </ref>
        <ref id="CR5">
          <label>5.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Boikos</surname>
                <given-names>SA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic</article-title>
            <source>JAMA Oncol.</source>
            <year>2016</year>
            <volume>2</volume>
            <fpage>922</fpage>
            <lpage>928</lpage>
            <pub-id pub-id-type="doi">10.1001/jamaoncol.2016.0256</pub-id>
            <pub-id pub-id-type="pmid">27011036</pub-id>
            <pub-id pub-id-type="pmcid">PMC5472100</pub-id>
          </element-citation>
        </ref>
        <ref id="CR6">
          <label>6.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Carney</surname>
                <given-names>JA</given-names>
              </name>
              <name name-style="western">
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad</article-title>
            <source>Am. J. Med. Genet.</source>
            <year>2002</year>
            <volume>108</volume>
            <fpage>132</fpage>
            <lpage>139</lpage>
            <pub-id pub-id-type="doi">10.1002/ajmg.10235</pub-id>
            <pub-id pub-id-type="pmid">11857563</pub-id>
          </element-citation>
        </ref>
        <ref id="CR7">
          <label>7.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Janeway</surname>
                <given-names>KA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations</article-title>
            <source>Proc. Natl Acad. Sci. USA</source>
            <year>2011</year>
            <volume>108</volume>
            <fpage>314</fpage>
            <lpage>318</lpage>
            <pub-id pub-id-type="doi">10.1073/pnas.1009199108</pub-id>
            <pub-id pub-id-type="pmid">21173220</pub-id>
            <pub-id pub-id-type="pmcid">PMC3017134</pub-id>
          </element-citation>
        </ref>
        <ref id="CR8">
          <label>8.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>McWhinney</surname>
                <given-names>SR</given-names>
              </name>
              <name name-style="western">
                <surname>Pasini</surname>
                <given-names>B</given-names>
              </name>
              <name name-style="western">
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
              <name name-style="western">
                <surname>International Carney</surname>
                <given-names>T</given-names>
              </name>
              <name name-style="western">
                <surname>Carney-Stratakis Syndrome</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Familial gastrointestinal stromal tumors and germ-line mutations</article-title>
            <source>N. Engl. J. Med.</source>
            <year>2007</year>
            <volume>357</volume>
            <fpage>1054</fpage>
            <lpage>1056</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMc071191</pub-id>
            <pub-id pub-id-type="pmid">17804857</pub-id>
          </element-citation>
        </ref>
        <ref id="CR9">
          <label>9.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Miettinen</surname>
                <given-names>M</given-names>
              </name>
              <name name-style="western">
                <surname>Fetsch</surname>
                <given-names>JF</given-names>
              </name>
              <name name-style="western">
                <surname>Sobin</surname>
                <given-names>LH</given-names>
              </name>
              <name name-style="western">
                <surname>Lasota</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases</article-title>
            <source>Am. J. Surg. Pathol.</source>
            <year>2006</year>
            <volume>30</volume>
            <fpage>90</fpage>
            <lpage>96</lpage>
            <pub-id pub-id-type="doi">10.1097/01.pas.0000176433.81079.bd</pub-id>
            <pub-id pub-id-type="pmid">16330947</pub-id>
          </element-citation>
        </ref>
        <ref id="CR10">
          <label>10.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Kleinbaum</surname>
                <given-names>EP</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor</article-title>
            <source>Int. J. Cancer</source>
            <year>2008</year>
            <volume>122</volume>
            <fpage>711</fpage>
            <lpage>718</lpage>
            <pub-id pub-id-type="doi">10.1002/ijc.23137</pub-id>
            <pub-id pub-id-type="pmid">17943734</pub-id>
          </element-citation>
        </ref>
        <ref id="CR11">
          <label>11.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Nishida</surname>
                <given-names>T</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Familial gastrointestinal stromal tumours with germline mutation of the KIT gene</article-title>
            <source>Nat. Genet</source>
            <year>1998</year>
            <volume>19</volume>
            <fpage>323</fpage>
            <lpage>324</lpage>
            <pub-id pub-id-type="doi">10.1038/1209</pub-id>
            <pub-id pub-id-type="pmid">9697690</pub-id>
          </element-citation>
        </ref>
        <ref id="CR12">
          <label>12.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Pasini</surname>
                <given-names>B</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Multiple gastrointestinal stromal and other tumors caused by platelet-derived growth factor receptor alpha gene mutations: a case associated with a germline V561D defect</article-title>
            <source>J. Clin. Endocrinol. Metab.</source>
            <year>2007</year>
            <volume>92</volume>
            <fpage>3728</fpage>
            <lpage>3732</lpage>
            <pub-id pub-id-type="doi">10.1210/jc.2007-0894</pub-id>
            <pub-id pub-id-type="pmid">17566086</pub-id>
          </element-citation>
        </ref>
        <ref id="CR13">
          <label>13.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Ricci</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Syndromic gastrointestinal stromal tumors</article-title>
            <source>Hered. Cancer Clin. Pract.</source>
            <year>2016</year>
            <volume>14</volume>
            <fpage>15</fpage>
            <pub-id pub-id-type="doi">10.1186/s13053-016-0055-4</pub-id>
            <pub-id pub-id-type="pmid">27437068</pub-id>
            <pub-id pub-id-type="pmcid">PMC4950812</pub-id>
          </element-citation>
        </ref>
        <ref id="CR14">
          <label>14.</label>
          <mixed-citation publication-type="other">Dubard Gault, M. et al. Germline SDHA mutations in children and adults with cancer. <italic toggle="yes">Cold Spring Harb. Mol. Case Stud.</italic>10.1101/mcs.a002584 (2018).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/mcs.a002584</pub-id><pub-id pub-id-type="pmcid">PMC6071569</pub-id><pub-id pub-id-type="pmid">30068732</pub-id></mixed-citation>
        </ref>
        <ref id="CR15">
          <label>15.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Jett</surname>
                <given-names>K</given-names>
              </name>
              <name name-style="western">
                <surname>Friedman</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Clinical and genetic aspects of neurofibromatosis 1</article-title>
            <source>Genet. Med.</source>
            <year>2010</year>
            <volume>12</volume>
            <fpage>1</fpage>
            <lpage>11</lpage>
            <pub-id pub-id-type="doi">10.1097/GIM.0b013e3181bf15e3</pub-id>
            <pub-id pub-id-type="pmid">20027112</pub-id>
          </element-citation>
        </ref>
        <ref id="CR16">
          <label>16.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Mandelker</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing</article-title>
            <source>JAMA</source>
            <year>2017</year>
            <volume>318</volume>
            <fpage>825</fpage>
            <lpage>835</lpage>
            <pub-id pub-id-type="doi">10.1001/jama.2017.11137</pub-id>
            <pub-id pub-id-type="pmid">28873162</pub-id>
            <pub-id pub-id-type="pmcid">PMC5611881</pub-id>
          </element-citation>
        </ref>
        <ref id="CR17">
          <label>17.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Casey</surname>
                <given-names>RT</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>SDHC epi-mutation testing in gastrointestinal stromal tumours and related tumours in clinical practice</article-title>
            <source>Sci. Rep.</source>
            <year>2019</year>
            <volume>9</volume>
            <fpage>10244</fpage>
            <pub-id pub-id-type="doi">10.1038/s41598-019-46124-9</pub-id>
            <pub-id pub-id-type="pmid">31308404</pub-id>
            <pub-id pub-id-type="pmcid">PMC6629852</pub-id>
          </element-citation>
        </ref>
        <ref id="CR18">
          <label>18.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Speight</surname>
                <given-names>RA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Rare, germline mutation of KIT with imatinib-resistant multiple GI stromal tumors and mastocytosis</article-title>
            <source>J. Clin. Oncol.</source>
            <year>2013</year>
            <volume>31</volume>
            <fpage>e245</fpage>
            <lpage>e247</lpage>
            <pub-id pub-id-type="doi">10.1200/JCO.2012.42.0133</pub-id>
            <pub-id pub-id-type="pmid">23610110</pub-id>
          </element-citation>
        </ref>
        <ref id="CR19">
          <label>19.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Zhang</surname>
                <given-names>LY</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy</article-title>
            <source>Leuk. Res.</source>
            <year>2006</year>
            <volume>30</volume>
            <fpage>373</fpage>
            <lpage>378</lpage>
            <pub-id pub-id-type="doi">10.1016/j.leukres.2005.08.015</pub-id>
            <pub-id pub-id-type="pmid">16183119</pub-id>
          </element-citation>
        </ref>
        <ref id="CR20">
          <label>20.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Mandelker</surname>
                <given-names>D</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group</article-title>
            <source>Ann. Oncol.</source>
            <year>2019</year>
            <volume>30</volume>
            <fpage>1221</fpage>
            <lpage>1231</lpage>
            <pub-id pub-id-type="doi">10.1093/annonc/mdz136</pub-id>
            <pub-id pub-id-type="pmid">31050713</pub-id>
            <pub-id pub-id-type="pmcid">PMC6683854</pub-id>
          </element-citation>
        </ref>
        <ref id="CR21">
          <label>21.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cheng</surname>
                <given-names>DT</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology</article-title>
            <source>J. Mol. Diagn.</source>
            <year>2015</year>
            <volume>17</volume>
            <fpage>251</fpage>
            <lpage>264</lpage>
            <pub-id pub-id-type="doi">10.1016/j.jmoldx.2014.12.006</pub-id>
            <pub-id pub-id-type="pmid">25801821</pub-id>
            <pub-id pub-id-type="pmcid">PMC5808190</pub-id>
          </element-citation>
        </ref>
        <ref id="CR22">
          <label>22.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cheng</surname>
                <given-names>DT</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing</article-title>
            <source>BMC Med. Genomics</source>
            <year>2017</year>
            <volume>10</volume>
            <fpage>33</fpage>
            <pub-id pub-id-type="doi">10.1186/s12920-017-0271-4</pub-id>
            <pub-id pub-id-type="pmid">28526081</pub-id>
            <pub-id pub-id-type="pmcid">PMC5437632</pub-id>
          </element-citation>
        </ref>
        <ref id="CR23">
          <label>23.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Zehir</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients</article-title>
            <source>Nat. Med.</source>
            <year>2017</year>
            <volume>23</volume>
            <fpage>703</fpage>
            <lpage>713</lpage>
            <pub-id pub-id-type="doi">10.1038/nm.4333</pub-id>
            <pub-id pub-id-type="pmid">28481359</pub-id>
            <pub-id pub-id-type="pmcid">PMC5461196</pub-id>
          </element-citation>
        </ref>
        <ref id="CR24">
          <label>24.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Cibulskis</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples</article-title>
            <source>Nat. Biotechnol.</source>
            <year>2013</year>
            <volume>31</volume>
            <fpage>213</fpage>
            <lpage>219</lpage>
            <pub-id pub-id-type="doi">10.1038/nbt.2514</pub-id>
            <pub-id pub-id-type="pmid">23396013</pub-id>
            <pub-id pub-id-type="pmcid">PMC3833702</pub-id>
          </element-citation>
        </ref>
        <ref id="CR25">
          <label>25.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>McKenna</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title>
            <source>Genome Res</source>
            <year>2010</year>
            <volume>20</volume>
            <fpage>1297</fpage>
            <lpage>1303</lpage>
            <pub-id pub-id-type="doi">10.1101/gr.107524.110</pub-id>
            <pub-id pub-id-type="pmid">20644199</pub-id>
            <pub-id pub-id-type="pmcid">PMC2928508</pub-id>
          </element-citation>
        </ref>
        <ref id="CR26">
          <label>26.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Karczewski</surname>
                <given-names>KJ</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title>
            <source>Nature</source>
            <year>2020</year>
            <volume>581</volume>
            <fpage>434</fpage>
            <lpage>443</lpage>
            <pub-id pub-id-type="doi">10.1038/s41586-020-2308-7</pub-id>
            <pub-id pub-id-type="pmid">32461654</pub-id>
            <pub-id pub-id-type="pmcid">PMC7334197</pub-id>
          </element-citation>
        </ref>
        <ref id="CR27">
          <label>27.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Richards</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>
            <source>Genet Med.</source>
            <year>2015</year>
            <volume>17</volume>
            <fpage>405</fpage>
            <lpage>424</lpage>
            <pub-id pub-id-type="doi">10.1038/gim.2015.30</pub-id>
            <pub-id pub-id-type="pmid">25741868</pub-id>
            <pub-id pub-id-type="pmcid">PMC4544753</pub-id>
          </element-citation>
        </ref>
        <ref id="CR28">
          <label>28.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Shen</surname>
                <given-names>R</given-names>
              </name>
              <name name-style="western">
                <surname>Seshan</surname>
                <given-names>VE</given-names>
              </name>
            </person-group>
            <article-title>FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing</article-title>
            <source>Nucleic Acids Res</source>
            <year>2016</year>
            <volume>44</volume>
            <fpage>e131</fpage>
            <pub-id pub-id-type="doi">10.1093/nar/gkw520</pub-id>
            <pub-id pub-id-type="pmid">27270079</pub-id>
            <pub-id pub-id-type="pmcid">PMC5027494</pub-id>
          </element-citation>
        </ref>
        <ref id="CR29">
          <label>29.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Niu</surname>
                <given-names>B</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>MSIsensor: microsatellite instability detection using paired tumor-normal sequence data</article-title>
            <source>Bioinformatics</source>
            <year>2014</year>
            <volume>30</volume>
            <fpage>1015</fpage>
            <lpage>1016</lpage>
            <pub-id pub-id-type="doi">10.1093/bioinformatics/btt755</pub-id>
            <pub-id pub-id-type="pmid">24371154</pub-id>
            <pub-id pub-id-type="pmcid">PMC3967115</pub-id>
          </element-citation>
        </ref>
        <ref id="CR30">
          <label>30.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name name-style="western">
                <surname>Alexandrov</surname>
                <given-names>LB</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Signatures of mutational processes in human cancer</article-title>
            <source>Nature</source>
            <year>2013</year>
            <volume>500</volume>
            <fpage>415</fpage>
            <lpage>421</lpage>
            <pub-id pub-id-type="doi">10.1038/nature12477</pub-id>
            <pub-id pub-id-type="pmid">23945592</pub-id>
            <pub-id pub-id-type="pmcid">PMC3776390</pub-id>
          </element-citation>
        </ref>
        <ref id="CR31">
          <label>31.</label>
          <mixed-citation publication-type="other">Alexandrov, L. <italic toggle="yes">SigProfiler</italic>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.mathworks.com/matlabcentral/fileexchange/38724-sigprofiler">https://www.mathworks.com/matlabcentral/fileexchange/38724-sigprofiler</ext-link>. (2022).</mixed-citation>
        </ref>
      </ref-list>
    </back>
  </article>
</pmc-articleset>
